常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-24.26/-13.97
|
|
企業價值
385.46M
|
| 資產負債 |
|
每股賬面淨值
15.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
61.00K
|
|
每股收益
2.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 15:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others. |

16.93 
